A new study published in The Journal of Dermatology revealed that patients with palmoplantar pustulosis (PPP) who were 18 ...

Some evidence suggests a higher risk of liver disease with psoriasis. Certain psoriasis treatments can cause liver toxicity, but the two conditions also share common risk factors, which may ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a pair of phase 3 trials. The Protagonist Therapeutics-partnered IL-23 ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing skin and easing symptom severity in patients with plaque psoriasis. Johnson ...

durable skin clearance and a safety profile similar to placebo in patients with plaque psoriasis. Upadacitinib efficacy and safety in treating palmoplantar pustulosis (PPP) revealed rapid and ...

"New treatment option for psoriasis discovered." ScienceDaily. www.sciencedaily.com / releases / 2025 / 03 / 250303141858.htm (accessed March 27, 2025). Explore More ...

During AAD 2025, psoriasis will be a key area of focus. Leading up to the event, which is occurring in Orlando, Florida, March 7-11, 2025, Dr. Alan D Kaye, Anesthesiology, Louisiana State University ...

If you have psoriasis, your skin’s needs will typically change with the seasons. Learn more about how you can prepare for this and avoid flare-ups. It is common for your skin care routine to ...

Psoriasis and dandruff can both trigger itching and flaky scalp skin. Psoriasis is a chronic autoimmune disorder that can cause thick patches of skin known as plaques on the scalp to become dry and ...

School of Chemical Engineering, Sungkyunkwan University (SKKU), Suwon 16419, Republic of Korea Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology ...

PsA occurs in up to 30% of patients with psoriasis, most commonly those aged ... subcutaneously in adult patients with palmoplantar pustulosis (PPP). The primary endpoint of the trial is percent ...